Urology In Focus: An Educational Series

Molecular Insights by Caris Life Sciences

This three-part educational series from Caris Life Sciences empowers urology professionals with foundational and advanced insights into molecular diagnostics. From understanding the basics of genetics and biomarker testing, to exploring the clinical value of tissue-based analysis and liquid biopsy, each session delivers actionable knowledge to enhance precision care and confident decision-making in urologic oncology.

• Genetic tests utilized in a urology clinic
• Germline, Prognostic, and Somatic
• Importance for the patient
• When to order
• Result implications

• Differences of various somatic tissue test (hot-spot, pan-tumor, pan-cancer, WES/WTS)
• Driver mutations / therapies (prostate and bladder)
• IHC and Protein overview
• Driver mutations / therapies (prostate and bladder)
• Digital Pathology / AI

• Differences of various somatic liquid tests
• Driver mutations / therapies (prostate and bladder)
• What is Clonal Hematopoiesis (CH) and what importance does it have in treatment
• Beyond therapy selection…disease monitoring, MRD, and MCED

Jason M. Hafron, MD

Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology (MIU). Dr. Hafron is a Professor of Urology at the William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan. He is experienced in all areas of adult urology, specializing in the minimally invasive treatment of cancers involving the prostate, kidney and bladder utilizing robotic surgery.
Dr. Hafron received his Bachelor of Science degree from the University of Michigan and his Doctor of Medicine degree from Loyola University Chicago-Stritch School of Medicine. Dr. Hafron completed his General Surgery and Urology Residency at Albert Einstein College of Medicine, Montefiore Medical Center in New York City. He continued his training as a Fellow in Advanced Laparoscopic and Robotic Surgery at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, Ohio. Dr. Hafron has published numerous peer reviewed journal articles on topics related to his expertise and presented his work at many national and international scientific meetings. He is the recipient of many clinical research awards. He is on the Editorial Board of the journal International Urology and Nephrology, Urologists in Cancer Care and Advances in Urology. He previously served on the Board of Directors of United Physicians Organization. Dr. Hafron is board certified in the specialty of Urology by the American Board of Urology.

David S. Morris, MD

Originally from Cleveland in East Tennessee, Dr. Morris attended The Baylor School in Chattanooga, TN. He graduated Summa Cum Laude from Vanderbilt University and then earned his doctorate from Vanderbilt University School of Medicine. Dr. Morris completed his residency training at The University of Michigan in Ann Arbor, MI with a special research interest in genetics that predict the aggressiveness of prostate and bladder cancers. Since completion of training, he has been with Urology Associates in Nashville, Tennessee. He serves the group as President and the Co-director for the Advanced Therapeutics Center. The ATC center also works closely with the Clinical Research Department as a center for multiple phase 2 and 3 trials primarily focused on GU oncology.

Gordon A. Brown, DO, FACOS

Gordon Brown, DO, FACOS, is an Associate Professor at Rowan University School of Osteopathic Medicine. He serves as Program Director of Urologic Surgery at Rowan University School of Osteopathic Medicine as well as Director of New Jersey Urology’s Center for Advanced Therapeutics, specializing in the treatment of prostate cancer. Board certified by the American Osteopathic Association, Dr. Brown completed a Urologic Oncology Fellowship at the UTMD Anderson Cancer Center in Houston, TX. He has been published in a variety of academic journals including JAMA Oncology, BJU International, and Prostate Cancer and Prostatic Diseases. Dr. Brown is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Urological Association.

This Innovation Theater webinar series is a paid program; LUGPA is not liable for the information presented.
Accuracy of the information presented is the responsibility of the advertiser.

Part 1

• Genetic tests utilized in a urology clinic
• Germline, Prognostic, and Somatic
• Importance for the patient
• When to order
• Result implications